Free Trial

TD Asset Management Inc Lowers Holdings in AstraZeneca PLC $AZN

AstraZeneca logo with Medical background

TD Asset Management Inc lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 18.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 908,339 shares of the company's stock after selling 199,851 shares during the quarter. TD Asset Management Inc's holdings in AstraZeneca were worth $63,475,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its holdings in AstraZeneca by 30.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company's stock valued at $1,003,124,000 after buying an additional 3,224,251 shares in the last quarter. Boston Partners boosted its position in shares of AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company's stock worth $368,712,000 after acquiring an additional 1,329,166 shares during the last quarter. Ameriprise Financial Inc. grew its stake in AstraZeneca by 5.6% during the first quarter. Ameriprise Financial Inc. now owns 4,942,367 shares of the company's stock valued at $364,283,000 after acquiring an additional 261,064 shares in the last quarter. Swedbank AB grew its stake in AstraZeneca by 20.8% during the second quarter. Swedbank AB now owns 4,077,554 shares of the company's stock valued at $284,939,000 after acquiring an additional 701,779 shares in the last quarter. Finally, WCM Investment Management LLC increased its holdings in AstraZeneca by 7.3% in the 1st quarter. WCM Investment Management LLC now owns 4,003,070 shares of the company's stock valued at $295,387,000 after acquiring an additional 272,537 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings reissued a "buy (b)" rating on shares of AstraZeneca in a report on Wednesday, October 8th. Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $86.00.

Get Our Latest Stock Report on AZN

AstraZeneca Stock Down 0.3%

Shares of NASDAQ:AZN opened at $84.83 on Thursday. The company has a market cap of $263.09 billion, a price-to-earnings ratio of 31.89, a PEG ratio of 1.56 and a beta of 0.36. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $79.82 and a 200 day moving average price of $73.69.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.24 earnings per share. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's payout ratio is 37.97%.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AstraZeneca Right Now?

Before you consider AstraZeneca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.

While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.